CCR5, the receptor of CCL3, was reported to increase the numbers of macrophages and T-cells in the lungs of patients with COPD, And the inhibition of CCR5 was considered as a viable treatment to reduce the inflammatory response COPD (Wang and He 2012; Costa et al., 2016; Ravi, Plumb et al., 2017). This evidence concerns the gene CCL3 and chronic obstructive pulmonary disease.